Donepezil Hydrochloride (Aricept)
ApprovedWithdrawn 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Severe Alzheimer's Disease
Conditions
Severe Alzheimer's Disease
Trial Timeline
Jan 1, 2008 โ โ
NCT ID
NCT00711204About Donepezil Hydrochloride (Aricept)
Donepezil Hydrochloride (Aricept) is a approved stage product being developed by Eisai for Severe Alzheimer's Disease. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00711204. Target conditions include Severe Alzheimer's Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00675025 | Phase 2 | Terminated |
| NCT00711204 | Approved | Withdrawn |
| NCT00165763 | Approved | Completed |
Competing Products
20 competing products in Severe Alzheimer's Disease